Search Results

Aldevron, a leading global manufacturer of DNA, RNA, and proteins used in cell and gene therapies and vaccine development, today announced it has entered a strategic partnership with Acuitas Therapeutics, Inc., a private biotechnology company specializing in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNPs).

BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service agreement under which BIOVECTRA will accept, on a non-exclusive basis, Acuitas’ best-in-class LNP technology platform for manufacturing mRNA-based therapeutics.

Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle delivery systems for molecular therapeutics.

IMUNON, Inc.(NASDAQ: IMNN) and Acuitas Therapeutics, a private biotechnology company focused on the development of delivery systems for nucleic acid vaccines and therapeutics based on lipid nanoparticles (LNP), today announced the signing of an agreement to evaluate the combination of IMUNON’s PLACCINE nucleic acid vaccine constructs formulated with Acuitas’ proprietary lipid delivery technology.

GC Biopharma and Acuitas Therapeutics announced that they have entered into a Development and Option agreement for Acuitas’ LNP technology.

Arbor Biotechnologies today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles (LNP).

Myeloid Therapeutics, Inc. (“Myeloid” or the “Company”), today announced that it has entered into an agreement with Acuitas Therapeutics (“Acuitas”), a global leader in developing LNP delivery systems that enable mRNA-based therapeutics.

Pfizer Inc. and Acuitas Therapeutics announced they have entered into a Development and Option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.